Will Current Clinical Trials Answer the Most Important Questions about Prostate Adenocarcinoma?

Ian M. Thompson, Thomas M. Seay

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Despite a heightened focus of the medical and research community on prostate cancer, many important questions about this disease remain unanswered. These include questions about the possible prevention of prostate cancer, as well as the optimal treatment approaches for localized, locally advanced, metastatic, and hormone-refractory disease. A whole host of prospective, well-designed clinical trials are currently in progress that should answer many of these questions. This review briefly explores some of these unresolved issues and describes ongoing trials designed to address them.

Original languageEnglish (US)
Pages (from-to)1109-1117
Number of pages9
JournalOncology
Volume11
Issue number8
StatePublished - 1997

Fingerprint

Prostate
Prostatic Neoplasms
Adenocarcinoma
Clinical Trials
Biomedical Research
Hormones

ASJC Scopus subject areas

  • Oncology

Cite this

Will Current Clinical Trials Answer the Most Important Questions about Prostate Adenocarcinoma? / Thompson, Ian M.; Seay, Thomas M.

In: Oncology, Vol. 11, No. 8, 1997, p. 1109-1117.

Research output: Contribution to journalArticle

Thompson, Ian M. ; Seay, Thomas M. / Will Current Clinical Trials Answer the Most Important Questions about Prostate Adenocarcinoma?. In: Oncology. 1997 ; Vol. 11, No. 8. pp. 1109-1117.
@article{01cf3dc775364497972652859abd2c16,
title = "Will Current Clinical Trials Answer the Most Important Questions about Prostate Adenocarcinoma?",
abstract = "Despite a heightened focus of the medical and research community on prostate cancer, many important questions about this disease remain unanswered. These include questions about the possible prevention of prostate cancer, as well as the optimal treatment approaches for localized, locally advanced, metastatic, and hormone-refractory disease. A whole host of prospective, well-designed clinical trials are currently in progress that should answer many of these questions. This review briefly explores some of these unresolved issues and describes ongoing trials designed to address them.",
author = "Thompson, {Ian M.} and Seay, {Thomas M.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "1109--1117",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Will Current Clinical Trials Answer the Most Important Questions about Prostate Adenocarcinoma?

AU - Thompson, Ian M.

AU - Seay, Thomas M.

PY - 1997

Y1 - 1997

N2 - Despite a heightened focus of the medical and research community on prostate cancer, many important questions about this disease remain unanswered. These include questions about the possible prevention of prostate cancer, as well as the optimal treatment approaches for localized, locally advanced, metastatic, and hormone-refractory disease. A whole host of prospective, well-designed clinical trials are currently in progress that should answer many of these questions. This review briefly explores some of these unresolved issues and describes ongoing trials designed to address them.

AB - Despite a heightened focus of the medical and research community on prostate cancer, many important questions about this disease remain unanswered. These include questions about the possible prevention of prostate cancer, as well as the optimal treatment approaches for localized, locally advanced, metastatic, and hormone-refractory disease. A whole host of prospective, well-designed clinical trials are currently in progress that should answer many of these questions. This review briefly explores some of these unresolved issues and describes ongoing trials designed to address them.

UR - http://www.scopus.com/inward/record.url?scp=0031205649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031205649&partnerID=8YFLogxK

M3 - Article

C2 - 9268974

AN - SCOPUS:0031205649

VL - 11

SP - 1109

EP - 1117

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 8

ER -